Amanote Research
Register
Sign In
Discover open access scientific publications
Search, annotate, share and cite publications
Publications by Bradley A. McGregor
Real‐World Assessment of Clinical Outcomes Among First‐Line Sunitinib Patients With Clear Cell Metastatic Renal Cell Carcinoma (mRCC) by the International mRCC Database Consortium Risk Group
Oncologist
Cancer Research
Medicine
Oncology
Circulating Tumor DNA Alterations in Advanced Urothelial Carcinoma and Association With Clinical Outcomes: A Pilot Study
European urology oncology
Oncology
Radiology
Urology
Nuclear Medicine
Imaging
Surgery
Related publications
Carcinoma of Unknown Primary Site (CUP) With Metastatic Renal Cell Carcinoma (mRCC) Histological and Immunohistochemical Characteristics (CUP-mRCC): Results From Consecutive Patients Treated With Targeted Therapy and Review of Literature
Clinical Genitourinary Cancer
Oncology
Urology
Clinical Impact of Targeted Therapies in Patients With Metastatic Clear-Cell Renal Cell Carcinoma
OncoTargets and Therapy
Oncology
Pharmacology
Anlotinib Versus Sunitinib as First‐Line Treatment for Metastatic Renal Cell Carcinoma: A Randomized Phase II Clinical Trial
Oncologist
Cancer Research
Medicine
Oncology
A Phase 2 Trial of Sunitinib in Patients With Advanced Non–clear Cell Renal Cell Carcinoma
European Urology
Urology
Sunitinib in the Treatment of Metastatic Renal Cell Carcinoma
Therapeutic Advances in Urology
Urology
Survival Benefits of Second-Line Axitinib Versus Everolimus After First Line Sunitinib Treatment in Metastatic Renal Cell Carcinoma
Pathology and Oncology Research
Medicine
Forensic Medicine
Pathology
Oncology
Cancer Research
Real-World Survival Outcomes and Prognostic Factors Among Patients Receiving First Targeted Therapy for Advanced Renal Cell Carcinoma: A SEER–Medicare Database Analysis
Clinical Genitourinary Cancer
Oncology
Urology
mRCC: Hohe Ansprechrate Unter Sunitinib Als Therapiekriterium
Uro-News
Pazopanib-Induced Liver Toxicity in Metastatic Renal Cell Carcinoma (mRCC) Patients: Impact of UGT1A1 Polymorphism on Pazopanib Dose Reduction, Safety and Patient Outcome
Clinical Genitourinary Cancer
Oncology
Urology
